On January 15, 2026, Novavax, Inc. entered into a License and Option Agreement with Pfizer Inc. collectively. The License and Option Agreement provides a non-exclusive, worldwide, license, to the Company's Matrix-M adjuvant technology (the Matrix-M Technology") for Pfizer to research, develop, and commercialize the Matrix-M Technology for use in vaccine products in at least one and up to two infectious diseases. The first field, (the First Field") has already been selected and the second field, (the Second Field"), is to be chosen at Pfizer's option, with certain limitations specified below (collectively, the Fields).
Under the License and Option Agreement, Pfizer shall have control of all matters relating to the development, manufacture and commercialization of any products that contain the adjuvant apart from the delivery and supply of the Adjuvant as detailed in the supply agreements which are contemplated under the License Option Agreement that the Parties intend to enter into. Second Field Option: The License and Option Agreement provides Pfizer the opportunity to license the Matrix-M technology in a Second Field that has not yet been specified but that Pfizer may designate at any time during the term (as specified in the License and Option Agreement). The Second Field may pertain to any infectious disease, so long as the Company does not already have a relevant IND filed or has previously granted an exclusive license or similar right pertaining to such infectious disease that would preclude such grant.
Pursuant to the License Agreement, the Company will receive an upfront payment of $30 million in the first quarter of 2026. Such forward-looking statements include, without limitation, statements regarding potential milestone payments and royalties, future vaccines made with the Company's Matrix-M Adjuvant technology, future supply agreements between the parties and the anticipated benefits of the transactions described herein, including the potential to generate revenue for the Company. Generally, forward-looking statements can be identified through the use of words or phrases such as believe, may, could, will, possible, potential, estimate, continue, ongoing, anticipate, intend, plan, plan, expect, should, would, aim, or assume, the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Novavax's current beliefs and expectations about the future of business, events and trends, and other future conditions.
